Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Cash from Financing Activities (2021 - 2025)

Historic Cash from Financing Activities for Prime Medicine (PRME) over the last 5 years, with Q3 2025 value amounting to $144.8 million.

  • Prime Medicine's Cash from Financing Activities rose 27585.49% to $144.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $151.0 million, marking a year-over-year decrease of 2301.13%. This contributed to the annual value of $195.9 million for FY2024, which is 2980473.28% up from last year.
  • Prime Medicine's Cash from Financing Activities amounted to $144.8 million in Q3 2025, which was up 27585.49% from $197000.0 recorded in Q2 2025.
  • Prime Medicine's 5-year Cash from Financing Activities high stood at $184.1 million for Q4 2022, and its period low was -$1.3 million during Q1 2022.
  • For the 5-year period, Prime Medicine's Cash from Financing Activities averaged around $33.0 million, with its median value being $134500.0 (2023).
  • As far as peak fluctuations go, Prime Medicine's Cash from Financing Activities crashed by 9989.46% in 2023, and later skyrocketed by 23126323.53% in 2024.
  • Quarter analysis of 5 years shows Prime Medicine's Cash from Financing Activities stood at -$1.1 million in 2021, then soared by 17049.63% to $184.1 million in 2022, then tumbled by 99.89% to $194000.0 in 2023, then crashed by 99.48% to $1000.0 in 2024, then skyrocketed by 14475200.0% to $144.8 million in 2025.
  • Its last three reported values are $144.8 million in Q3 2025, $197000.0 for Q2 2025, and $6.0 million during Q1 2025.